Michigan Med University of Michigan .
Welcome,         Profile    Billing    Logout  
 2 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Talpaz, Moshe
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Asciminib, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Active, not recruiting
3
115
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
07/24
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT05320198: Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Recruiting
1/2
56
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
10/24
10/24
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25
McCullough, Nancy
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Asciminib, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Active, not recruiting
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24

Download Options